Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
RESEARCH TOOLSreports
Holding TSE:MDP?
Track your performance easily
MDP Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.44 - C$3.47
Previous CloseC$2.65
Volume11.30K
Average Volume (3M)30.34K
Market Cap
C$64.99M
Enterprise ValueC$124.73M
Total Cash (Recent Filing)$8.21M
Total Debt (Recent Filing)$52.29M
Price to Earnings (P/E)53.3
Beta1.57
Next Earnings
Nov 06, 2024EPS Estimate
C$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding24,458,673
10 Day Avg. Volume17,533
30 Day Avg. Volume30,339
Standard Deviation0.24
R-Squared0.13
Alpha0.00796
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)0.41
Price to Cash Flow (P/CF)2.20
P/FCF Ratio1.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda6.32
Forecast
1Y Price Target
C$2.69Price Target Upside0.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Pharmaceuticals Reports Mixed Q1 2025 Results
PremiumPre-Earnings
Is MDP a Buy, Before Earnings?
PremiumCompany Announcements
Medexus Pharmaceuticals Schedules Q1 2025 Earnings Call
PremiumCompany Announcements
Medexus Pharmaceuticals Hits Record Revenue
PremiumCompany Announcements
Medexus Pharmaceuticals Announces Upcoming Earnings Call
PremiumCompany Announcements
Medexus Awaits FDA Decision on TreosulfanPremiumCompany Announcements
Medexus Pharmaceuticals Accepts Metoject® RulingBulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA has accepted the New Drug Application resubmission for treosulfan in combination with fludarabine for allogeneic hematopoietic stem cell transplantation.
Financial PerformanceThe price target has been raised to $3.30/shr from $3.00/shr due to an increased probability of treosulfan approval to 75%.
Market PotentialTreosulfan’s market potential becomes more visible and significant, yet the market continues to be significantly underestimating the drug’s long-term value.
Bears Say
EarningsMedexus reported FY4Q-2024 financial results coming in slightly below estimates.
Financial PerformanceThe FY1Q-2025 financial results reported were mixed, indicating some uncertainties.
Product GrowthStalled growth awaits the Treosulfan.
---
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.44 and its highest was C$3.47 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2024 which is in 55 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Aug 07, 2024. The company reported C$0.108 earnings per share for the quarter, beating the consensus estimate of C$0.068 by C$0.041.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is C$0.01.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 24,525,540 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0.108 in its last earnings report, beating expectations of C$0.068. Following the earnings report the stock price went up 8.37%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$2.69 (0.37% Upside)
C$2.69 (0.37% Upside)
Insider Transactions
Bought Shares
Worth C$49.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.69%
12-Months-Change
Fundamentals
Return on Equity
4.05%
Trailing 12-Months
Asset Growth
-8.74%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
---
MDP Stock 12 Month Forecast
Average Price Target
C$2.69
▲(0.37% Upside)
Technical Analysis
HLS Therapeutics Inc
―
Quipt Home Medical
―
Resverlogix
―
Reliq Health Technologies
―
Best Analysts Covering MDP
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+67.46%
reiterated a buy rating 2 months ago
Copying Tania Armstrong-Whitworth's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +67.46% per trade.
---